ArticleTranslational lung cancer research2025
Dual-layer spectral detector computed tomography multiparameter machine learning model for prediction of invasive lung adenocarcinoma.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spectral CT-based intratumoral and peritumoral radiomics for predicting invasiveness of ground-glass nodules in lung adenocarcinoma.La Radiologia medica · 2026Article
- Artificial intelligence construction: a review of the bridge between CT imaging features of lung ground-glass nodules adenocarcinoma and carcinogenic driver genes.Journal of cancer research and clinical oncology · 2026Review
- A radiomics-based nomogram for preoperatively predicting the invasiveness of nodular lung adenocarcinoma: a multicenter study.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the leading cause of cancer-related deaths. High-resolution computed tomography (HRCT) has improved the detection of ground glass nodules (GGNs), which are early indicators of lung cancer. Accurate assessment of GGN invasiveness is crucial for determining the appropriate surgical approach. Dual-layer spectral detector computed tomography (DLCT) offers advanced imaging capabilities, including electron density and iodine density, which enhance the evaluation of GGN invasiveness. This study aims to develop a machine learning (ML) model that integrates DLCT parameters and clinical features to predict the invasiveness of GGNs in LUAD, aiding in surgical decision-making and prognosis improvement. Methods: The retrospective study encompassed 272 patients who were diagnosed with LUAD, comprising 154 cases of invasive adenocarcinomas (IA) and 118 cases of pre-invasive minimally invasive adenocarcinoma (MIA) which were then randomly allocated into a training set and a test set. Six ML models were developed based on five DLCT parameters (conventional, iodine density, virtual noncontrast, electron density, and effective atomic number). Subsequently, a nomogram was constructed using multi-factor logistic regression, incorporating radiomic characteristics and clinicopathological risk factors. Results: The ML model based on conventional plus electron density performed better than the models with other DLCT parameters, with the area under the curves (AUCs) of 0.945 and 0.964 in the training and test sets, respectively. The clinical model and radiomics score (Rad-score) were combined in the logistic regression to construct a joint model, of which the AUCs were 0.974 in the training sets and 0.949 in the test sets. The ML model effectively differentiated between IA and pre-invasive MIA, and further classified patients into high and medium risk categories for invasion using waterfall plots. Conclusions: The ML model based on DLCT parameters helps predict the invasiveness of GGNs and classifies the GGNs into different risk grades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.